Cargando…

Parametrial involvement and decreased survival of women with FIGO stage IIIC1 cervical cancer

OBJECTIVE: To evaluate the effect of parametrial status on FIGO stage IIIC1 cervical cancer. METHODS: A retrospective study was conducted from June 1, 2009, to December 31, 2018.Patients with stage IIIC1 cervical cancer were included and stratified into two groups based on the status of parametrial...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Hong, Wang, Ming, Liu, Yang, Wu, Yumei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323298/
https://www.ncbi.nlm.nih.gov/pubmed/36929577
http://dx.doi.org/10.3802/jgo.2023.34.e46
_version_ 1785068935516782592
author Chang, Hong
Wang, Ming
Liu, Yang
Wu, Yumei
author_facet Chang, Hong
Wang, Ming
Liu, Yang
Wu, Yumei
author_sort Chang, Hong
collection PubMed
description OBJECTIVE: To evaluate the effect of parametrial status on FIGO stage IIIC1 cervical cancer. METHODS: A retrospective study was conducted from June 1, 2009, to December 31, 2018.Patients with stage IIIC1 cervical cancer were included and stratified into two groups based on the status of parametrial involvement. Patients with IIIA or IIIB were selected as control. The primary outcomes are overall survival (OS) and progression-free survival (PFS). RESULTS: Of 586 patients included, 377 patients were stage IIIC1 (group A) and 209 patients were stage IIIA/IIIB (group B). Compared control, stage IIIC1 was not associated with worse 5-year OS or PFS. Of the stage IIIC1 patients, 58.1% without parametrial involvement (group A1) and 41.9% with parametrial involvement (group A2). Patients of group A1 showed a better prognosis than group A2 both in 5-year rates of OS (79.09% vs. 59.43%, p<0.001) and PFS (73.27% vs. 56.95%, p=0.0002). However, patients of group A1 showed a better prognosis than group B both in OS and PFS. Also, patients of group A2 showed a comparable prognosis to group B both in OS and PFS. CONCLUSION: Reclassification of stage IIIC1 cervical cancer without parametrial into a new stage is more appropriate and improves discriminatory ability.
format Online
Article
Text
id pubmed-10323298
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology
record_format MEDLINE/PubMed
spelling pubmed-103232982023-07-07 Parametrial involvement and decreased survival of women with FIGO stage IIIC1 cervical cancer Chang, Hong Wang, Ming Liu, Yang Wu, Yumei J Gynecol Oncol Original Article OBJECTIVE: To evaluate the effect of parametrial status on FIGO stage IIIC1 cervical cancer. METHODS: A retrospective study was conducted from June 1, 2009, to December 31, 2018.Patients with stage IIIC1 cervical cancer were included and stratified into two groups based on the status of parametrial involvement. Patients with IIIA or IIIB were selected as control. The primary outcomes are overall survival (OS) and progression-free survival (PFS). RESULTS: Of 586 patients included, 377 patients were stage IIIC1 (group A) and 209 patients were stage IIIA/IIIB (group B). Compared control, stage IIIC1 was not associated with worse 5-year OS or PFS. Of the stage IIIC1 patients, 58.1% without parametrial involvement (group A1) and 41.9% with parametrial involvement (group A2). Patients of group A1 showed a better prognosis than group A2 both in 5-year rates of OS (79.09% vs. 59.43%, p<0.001) and PFS (73.27% vs. 56.95%, p=0.0002). However, patients of group A1 showed a better prognosis than group B both in OS and PFS. Also, patients of group A2 showed a comparable prognosis to group B both in OS and PFS. CONCLUSION: Reclassification of stage IIIC1 cervical cancer without parametrial into a new stage is more appropriate and improves discriminatory ability. Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2023-03-13 /pmc/articles/PMC10323298/ /pubmed/36929577 http://dx.doi.org/10.3802/jgo.2023.34.e46 Text en © 2023. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Chang, Hong
Wang, Ming
Liu, Yang
Wu, Yumei
Parametrial involvement and decreased survival of women with FIGO stage IIIC1 cervical cancer
title Parametrial involvement and decreased survival of women with FIGO stage IIIC1 cervical cancer
title_full Parametrial involvement and decreased survival of women with FIGO stage IIIC1 cervical cancer
title_fullStr Parametrial involvement and decreased survival of women with FIGO stage IIIC1 cervical cancer
title_full_unstemmed Parametrial involvement and decreased survival of women with FIGO stage IIIC1 cervical cancer
title_short Parametrial involvement and decreased survival of women with FIGO stage IIIC1 cervical cancer
title_sort parametrial involvement and decreased survival of women with figo stage iiic1 cervical cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323298/
https://www.ncbi.nlm.nih.gov/pubmed/36929577
http://dx.doi.org/10.3802/jgo.2023.34.e46
work_keys_str_mv AT changhong parametrialinvolvementanddecreasedsurvivalofwomenwithfigostageiiic1cervicalcancer
AT wangming parametrialinvolvementanddecreasedsurvivalofwomenwithfigostageiiic1cervicalcancer
AT liuyang parametrialinvolvementanddecreasedsurvivalofwomenwithfigostageiiic1cervicalcancer
AT wuyumei parametrialinvolvementanddecreasedsurvivalofwomenwithfigostageiiic1cervicalcancer